Tobam Sells 3,857 Shares of West Pharmaceutical Services, Inc. $WST

Tobam lessened its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 19.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,338 shares of the medical instruments supplier’s stock after selling 3,857 shares during the period. West Pharmaceutical Services accounts for about 1.6% of Tobam’s portfolio, making the stock its 23rd largest position. Tobam’s holdings in West Pharmaceutical Services were worth $4,286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in WST. Empowered Funds LLC increased its position in shares of West Pharmaceutical Services by 16.1% during the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after acquiring an additional 224 shares during the period. Intech Investment Management LLC grew its stake in West Pharmaceutical Services by 27.7% in the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after purchasing an additional 1,307 shares in the last quarter. Acadian Asset Management LLC increased its holdings in West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after purchasing an additional 157 shares during the period. CWM LLC raised its position in West Pharmaceutical Services by 58.3% during the 2nd quarter. CWM LLC now owns 2,340 shares of the medical instruments supplier’s stock valued at $512,000 after purchasing an additional 862 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in West Pharmaceutical Services by 13.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,592 shares of the medical instruments supplier’s stock valued at $799,000 after purchasing an additional 420 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Up 2.6%

NYSE:WST opened at $249.99 on Monday. The company’s 50-day simple moving average is $260.95 and its 200-day simple moving average is $261.70. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02. West Pharmaceutical Services, Inc. has a fifty-two week low of $187.43 and a fifty-two week high of $322.34. The stock has a market capitalization of $17.98 billion, a P/E ratio of 36.82, a P/E/G ratio of 3.27 and a beta of 1.18.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, topping the consensus estimate of $1.83 by $0.21. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The firm had revenue of $805.00 million during the quarter, compared to analyst estimates of $795.70 million. During the same quarter in the previous year, the business posted $1.82 EPS. West Pharmaceutical Services’s revenue was up 7.5% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, equities analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Wednesday, January 28th. West Pharmaceutical Services’s dividend payout ratio is currently 12.96%.

Analyst Upgrades and Downgrades

WST has been the topic of several research reports. KeyCorp raised their price target on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, October 24th. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. TD Cowen started coverage on shares of West Pharmaceutical Services in a report on Wednesday, October 29th. They issued a “buy” rating for the company. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $314.56.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Beat-and-guide: WST reported Q4 EPS of $2.04 vs. $1.83 consensus and revenue of $805M, and issued FY‑2026 EPS guidance of $7.85–$8.20 with revenue ~$3.2–3.3B — the core reason investors pushed the stock higher. West Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Strong demand for drug components: Reuters highlights management’s forecast for 2026 profit above estimates driven by robust demand for HVP components (syringes, cartridges), supporting margin and cash‑flow outlook. West Pharma forecasts 2026 profit above estimates on strong demand for drug components
• Positive Sentiment: Proprietary product progress and outlook: Company commentary and analyst notes emphasize SmartDose and HVP-led growth, with management signaling SmartDose sale activity by mid‑2026 — a potential revenue/margin driver. WST’s Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up
• Positive Sentiment: Analyst support: TD Cowen reiterated a Buy and kept a $350 price target, citing non‑GLP‑1 growth, margin expansion and regulatory tailwinds — reinforcing investor confidence. Buy Rating on West
• Positive Sentiment: Market reaction coverage: Multiple outlets (Yahoo, Seeking Alpha, TipRanks) note stock strength following results and outlook, reflecting broad positive market reception. West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook
• Neutral Sentiment: Guidance detail and call transcript: The full earnings call transcript and slide deck provide execution details and cadence for HVP and SmartDose commercialization — useful for modeling but not new directional news. West Pharmaceutical Services Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Peer/value comparison: A Zacks piece compares Cooper (COO) and WST for value seekers — useful for allocation decisions but not directly driving WST’s move. COO vs. WST: Which Stock Is the Better Value Option?
• Neutral Sentiment: Macro market commentary: Coverage noting WST’s role in broader indices/futures is descriptive — relevant for positioning but secondary to fundamentals. Is West Pharmaceutical Services (NYSE:WST) a Pillar In S&P 500 Futures Performance
• Negative Sentiment: Relative underperformance note: MarketWatch flags that WST has underperformed some competitors recently despite daily gains — a reminder of sector competition and potential valuation scrutiny. West Pharmaceutical Services Inc. stock underperforms despite daily gains

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.